At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Pembrolizumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Trial of Consolidation Pembrolizumab After Concurrent Chemotherapy and Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Pembrolizumab for Non-small Cell Lung Cancer. Completed, enrolled 32 participants across 1 site.
Detailed Summary
The main purpose of this study is to assess the safety, tolerability and anti-tumor activity of the experimental study drug pembrolizumab (also known as Keytruda or MK-3475) in people with non-small cell lung cancer (NSCLC) that has come back after radiation therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 2017
Enrollment StartNov 2017
Primary CompletionSep 2023
TodayJul 2026
First PostedMar 22, 2017
Enrollment StartNov 29, 2017
Primary CompletionSep 12, 2023
TodayJul 2, 2026
Enrollment to primary: 5.8 yearsPosted 9.3 years ago
Interventions
Pembrolizumabdrug
Concurrent Pembrolizumab after proton reirradiation